> Detailanzeige

Schütte, Kerstin; Kupčinskas, Juozas; Morkunas, Egidijus; Öcal, Osman; Schinner, Regina; Seidensticker, Max; De Toni, Enrico N.; Ben Khaled, Najib; Pech, Maciej; Palmer, Daniel; Berg, Thomas; Sengel, Christian; Basu, Bristi; Valle, Juan W.; Benckert, Julia; Gasbarrini, Antonio; Sangro, Bruno; Malfertheiner, Peter; Ricke, Jens

Dynamics in Circulating Proinflammatory Biomarkers for Prognostic Assessment of Patients With Advanced HCC – A Substudy From the SORAMIC Trial

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Dynamics in Circulating Proinflammatory Biomarkers for Prognostic Assessment of Patients With Advanced HCC – A Substudy From the SORAMIC Trial
  • Beteiligte: Schütte, Kerstin; Kupčinskas, Juozas; Morkunas, Egidijus; Öcal, Osman; Schinner, Regina; Seidensticker, Max; De Toni, Enrico N.; Ben Khaled, Najib; Pech, Maciej; Palmer, Daniel; Berg, Thomas; Sengel, Christian; Basu, Bristi; Valle, Juan W.; Benckert, Julia; Gasbarrini, Antonio; Sangro, Bruno; Malfertheiner, Peter; Ricke, Jens
  • Erschienen: Frontiers Media SA, 2022
  • Erschienen in: Frontiers in Gastroenterology
  • Sprache: Nicht zu entscheiden
  • DOI: 10.3389/fgstr.2022.939192
  • ISSN: 2813-1169
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:sec><jats:title>Introduction</jats:title><jats:p>Prediction of response to treatment in patients with advanced hepatocellular carcinoma (HCC) may assist in the selection of personalized management.</jats:p></jats:sec><jats:sec><jats:title>Objective</jats:title><jats:p>This exploratory analysis of the palliative arm of the SORAMIC trial (ClinicalTrials.gov NCT01126645) evaluated the prognostic potential of basal and dynamic changes in systemic levels of interleukin 6 (IL-6), interleukin 8 (IL-8), systemic vascular endothelial growth factor (VEGF), and lipopolysaccharide (LPS).</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We evaluated the correlations between overall survival (OS) and concentrations of IL-6, IL-8, VEGF, and LPS at follow-up approximately 7-9 weeks after treatment initialization (FU) compared to baseline (BL) in 90 patients treated either with <jats:sup>90</jats:sup>Yttrium (<jats:sup>90</jats:sup>Y) microspheres combined with sorafenib (n = 44) or with sorafenib (n = 46) alone.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Changes in IL-6 concentration during treatment showed correlations with the outcome. An increase in IL-6 concentration of less than 16.8 pg/mL over baseline readings was associated with better survival [median OS 16.3 months compared with 8.9 months (p = 0.0354)]. Correlations with survival were not observed for VEGF or LPS concentrations at baseline, at FU, or changes between these time points.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Changes in IL 6 serum levels at 7-9 weeks after treatment initialization but not in IL 8, VEGF, or LPS add important information on the outcome of advanced HCC patients treated palliatively within the SORAMIC trial.</jats:p></jats:sec>
  • Zugangsstatus: Freier Zugang